



Spirea appoints Scientific Advisory Board of international ADC experts

Cambridge, UK, 09 January 2023: Spirea Limited, a biopharmaceutical company developing a new generation of antibody drug conjugate (ADC) therapeutics, is delighted to announce that Prof John Hartley, Dr Anthony Tolcher, Dr Rakesh Dixit, and Dr Paul Varley will be joining its Scientific Advisory Board (SAB).

The newly formed SAB will play a key role in providing an external and objective perspective on the company's scientific strategy and will assist in the process of shaping its therapeutic portfolio and advancing products through to the clinic.

Prof Hartley, Dr Tolcher, Dr Dixit and Dr Varley bring a wealth of experience in ADC development to Spirea as the company continues to build on the potential of its unique linker platform technology to advance a pipeline of ADCs that enable more cytotoxic drug to be attached to a targeting antibody resulting in the delivery of more drug payload to the target cancer cell.

"We are thrilled to welcome John, Tony, Rakesh and Paul as SAB members" said Myriam Ouberai, Ph.D., Chief Executive Officer of Spirea. "Their expertise in ADC drug development will be invaluable to the company as we advance our pipeline of ADC therapeutics to radically improve the treatment options for patients with hard-to-treat cancers. It is a testimony to the relevance of our novel approach to building ADC therapeutics that they have agreed to be part of our journey."

Spirea's Scientific Advisory Board

Prof John Hartley is Professor of Cancer Studies at UCL. He is also Scientific Lead of the UCL Experimental Cancer Medicine Centre. Prior to joining UCL he was a Visiting Fellow at the National Cancer Institute, USA and an Alberta Heritage Research Fellow at the University of Alberta, Canada. Prof Hartley was one of the founders of Spirogen Ltd, which was acquired by AstraZeneca in 2013. He is author or co-author of more than 300 peer-reviewed publications in the fields of cancer research and cancer therapeutics and is a Fellow of both the Royal Societies of Biology and Chemistry and an Honorary Member of the Royal College of Radiologists. Since 2000 he has also been Chair of the Protocol Safety and Review Board of Cancer Research UK.

Dr Anthony Tolcher is a Board-Certified Medical Oncologist and is the Founder and CEO of NEXT Oncology, a clinical research organization dedicated to advancing highly innovative cancer medicines to first-in-human clinical trials. Dr Tolcher was also Co-Founder of South Texas Accelerated Research

Therapeutics, managing a network of global clinical trial centers across the America, Europe and Asia. Dr Tolcher has led and supervised many early-stage clinical trials with highly innovative, targeted cancer therapies, including ADCs, and is the author or co-author of more than 130 peer-reviewed publications in the field of Medical and Clinical Oncology. Dr Tolcher is an internationally recognised key opinion leader in the clinical validation of ADCs.

Dr Rakesh Dixit is a highly experienced executive, inventor, and scientist with over 35 years of senior roles at high profile pharmaceutical companies, including Merck, Johnson & Johnson, and AstraZeneca. He is currently the President and CSO of Regio Biosciences and Bionavigen and is on the scientific advisory boards of several ADC companies. Dr Dixit has extensive experience in developing biologics and small-molecule biopharmaceuticals with particular expertise in discovery, preclinical development, safety assessment, DMPK, and translational sciences. He is a Diplomate and is Board Certified in Toxicology with the American Board of Toxicology. Dr Dixit is regularly invited to be a presenter, workshop leader, chair and panellist at international research conferences and is internationally recognised as a key opinion leader in ADC drug discovery and development. Dr Dixit was also winner of the “Long Standing Contributions to ADCs” award by his peers at the World ADC Forum in 2020.

Dr Paul Varley is an expert and leader in biopharmaceutical development with over 25 years’ experience in senior roles at high profile biotechnology and pharmaceutical companies including AstraZeneca, MedImmune, Kymab and currently, Alchemab. He has played a key role in advancing multiple drug programmes into the clinic and through to commercialization. Dr Varley has, until recently, been a member of the British Pharmacopoeia (BP) Commission and Chair of BP Expert Advisory Group on Biological and Biotechnological Products (2013 – 2021). He also currently chairs a MHRA/BP working party on new standards for Biological Medicines (DPS) and is also a member of the European Pharmacopoeia (EP) Expert Committee on Monoclonal Antibodies. Paul was a founder of the BIA COVID-19 antibody Task Force and was a member of the UK BIA vaccine Manufacturing Advisory Group which supported the UK Vaccine task Force.

For further information about Spirea, please visit: www.spirea.co.uk

ENDS

About Spirea www.spirea.co.uk

Spirea is advancing an exciting and innovative pipeline of antibody drug conjugates that allow more drug payload to be specifically directed to the target of interest on the tumour cell. This results in an increase in therapeutic effect whilst substantially reducing debilitating side-effects. By delivering the right amount of the right drug to the right cells, Spirea’s proprietary technology will unlock a new generation of accessible, powerful and well-tolerated medicines for the treatment of a wide range of cancers. As well as developing its own drugs, Spirea will collaborate with partners on new

programmes and to revive pre-existing preclinical and clinical-stage assets that have failed because of narrow therapeutic indexes.